NCT07550010 Digital Telecytology for Triage of HPV-Positive Women in Cameroon
| NCT ID | NCT07550010 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Human Papillomavirus Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2026-09-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,800 participants in total. It began in 2025-09-08 with a primary completion date of 2026-09-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings
Eligibility Criteria
Inclusion Criteria: * HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old * Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF). Exclusion Criteria: * Pregnancy at the time of screening * Previous hysterectomy * Known cervical cancer * Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass) * Conditions that can interfere with visualization of the cervix * Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure) * Women who are not able to comply with the study protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07550010 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 50 Years, studying Human Papillomavirus Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07550010 currently recruiting?
Yes, NCT07550010 is actively recruiting participants. Contact the research team at patrick.petignat@hug.ch for enrollment information.
Where is the NCT07550010 trial being conducted?
This trial is being conducted at Yaoundé, Cameroon, Yaoundé, Cameroon.
Who is sponsoring the NCT07550010 clinical trial?
NCT07550010 is sponsored by University Hospital, Geneva. The trial plans to enroll 1,800 participants.